Discussion
Givlaari (givosiran), an approved therapy for acute hepatic porphyria (AHP), was associated with several potentially new safety signals not included in the therapy’s prescribing information, according to a large real-world safety analysis. By analyzing more than 1,200 reports of adverse events associated with Givlaari in a U.S. drug safety…